Skip to main content
. 2021 Sep 28;27(36):6079–6092. doi: 10.3748/wjg.v27.i36.6079

Figure 5.

Figure 5

miR-588 can target cylindromatosis in gastric cancer cells. A: The binding site of miR-588 and cylindromatosis (CYLD) was predicted in TargetScan database; B-D: After cisplatin (DDP)-resistant SGC7901 cells were treated with miR-588 mimic, the luciferase activity of CYLD was measured by luciferase reporter assays (B); the expression of CYLD was determined by qPCR (C); and the expression of CYLD was measured by Western blot analysis (D). Data shown are the mean ± SD. bP < 0.01. CYLD: Cylindromatosis.